Details of the Drug
General Information of Drug (ID: DMWY1QN)
Drug Name |
1,2-Bis-(3-methoxy-phenyl)-ethane-1,2-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
40101-17-5; 3,3'-Dimethoxybenzil; 1,2-bis(3-methoxyphenyl)ethane-1,2-dione; Ethanedione, bis(3-methoxyphenyl)-; 1,2-Ethanedione, 1,2-bis(3-methoxyphenyl)-; PJGXOGKIVAJFTE-UHFFFAOYSA-N; MFCD00038221; Bis(3-methoxyphenyl)ethanedione; EINECS 254-793-5; ACMC-20a2cz; 3,3'-dimethoxy benzil; AC1Q5BUM; AC1L3WPM; 3,3'-Dimethoxydibenzoyl; Bis(3-methoxyphenyl)glyoxal; Benzil-based compound, 22; CHEMBL435109; SCHEMBL2156482; 3,3'-Dimethoxybenzil, 99%; DTXSID7068213; BDBM22744; CTK4I2455; 3,3''-Dimethoxybenzil, 99+%; ZINC2168289; 5327AB
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 270.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||